Evidence map›Paper›PMID 37859414›Full record

ArticleParasitology2023

Anti-

Bruna Ramos Dos Santos, Amanda Bruno da Silva Bellini Ramos, Renata Priscila Barros de Menezes, Marcus Tullius Scotti, Fábio Antônio Colombo, Marcos José Marques, Juliana Quero Reimão

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasitology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Antimicrobial agents and chemotherapy · 2026
    Article
  2. Novel drug candidates targetingFrontiers in pharmacology · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bruna Ramos Dos SantosDepartamento de Morfologia e Patologia Básica, Faculdade de Medicina de Jundiaí, Laboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (PARASITTOS), Jundiaí, Brazil.
Amanda Bruno da Silva Bellini RamosDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas, Brazil.
Renata Priscila Barros de MenezesPrograma de Pós-graduação em Produtos Naturais e Sintéticos Bioativos (PgPNSB), Instituto de Pesquisa em Fármacos e Medicamentos (IPeFarM), Universidade Federal da Paraíba, Campus I, Cidade Universitária, João Pessoa, Brazil.
Marcus Tullius ScottiPrograma de Pós-graduação em Produtos Naturais e Sintéticos Bioativos (PgPNSB), Instituto de Pesquisa em Fármacos e Medicamentos (IPeFarM), Universidade Federal da Paraíba, Campus I, Cidade Universitária, João Pessoa, Brazil.ORCID 0000-0003-4863-8057
Fábio Antônio ColomboDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas, Brazil.
Marcos José MarquesDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas, Brazil.
Juliana Quero ReimãoDepartamento de Morfologia e Patologia Básica, Faculdade de Medicina de Jundiaí, Laboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (PARASITTOS), Jundiaí, Brazil.ORCID 0000-0002-4418-0838

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/18954-4Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/03399-5
6 · The paper itself

Abstract

Toxoplasmosis is a significant public health concern with limited therapeutic options. The medicines for malaria venture (MMV) developed the pandemic response box (PRB) containing 400 drug-like molecules with broad pathogen activity. The aim of this work is to evaluate PRB compounds for their anti-

Indexed as

MalariaToxoplasmaAnimalsImidazolesMiceMolecular Docking SimulationPandemicsPyridinesImidazolesPyridinesRWJ 67657antitoxoplasmic compoundbioinformaticsdrug discoverydrug repurposingmicepandemic response boxRWJ-67657screeningToxoplasma gondiitoxoplasmosis

Identifiers

PMID37859414
PMCPMC10941209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.